Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018, Case Western Reserve University
A new swallowable balloon sampling device that could help with minimally invasive screening procedure for esophageal cancer risk. Credit: Case Western Reserve University School of Medicine

Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise for preventing deaths from esophageal adenocarcinoma.

Barrett's (BE) is the precursor lesion of esophageal adenocarcinoma (EAC), a highly lethal cancer with more than 80 percent mortality at five years. Lethal EAC can be prevented when patients are diagnosed at the precursor stage of Barrett's esophagus, and early foci of near cancerous changes (dysplasias) are ablated. However, detection of BE has traditionally necessitated endoscopy, an expensive and invasive that requires sedation and is thus unsuitable as a method for wide BE screening. In a significant step forward, the team has developed an easy, five minute outpatient test that is more than 90 percent sensitive for detecting individuals with BE. Patients simply swallow a vitamin pill sized balloon that swabs the esophagus, and that, after retrieval through the mouth, is tested for DNA abnormalities that the investigators discovered are diagnostic of BE. A study describing the development of the test and the results from its clinical trial in patients has been published in today's issue of Science Translational Medicine.

The swallowable balloon device was developed by Case Western Reserve School of Medicine faculty and University Hospitals physicians Amitabh Chak, MD (Professor of Medicine and head of the NIH-Case Barrett's Esophagus Translational Research Network "BETRNet" program), Joseph Willis, MD (Professor of Pathology and Pathology Vice-Chair for Clinical Affairs), and Sanford Markowitz, MD, PhD (Ingalls Professor of Cancer Genetics and head of the NIH-Case GI Cancers "SPORE" Program of Research Excellence). Helen Moinova, PhD, study first author and instructor at Case Western Reserve School of Medicine, led a parallel effort within the Markowitz laboratory to identify DNA changes diagnostic of Barrett's. Using genome-wide sequencing approaches, Dr. Moinova identified two genes, VIM and CCNA1, that each get chemically modified by DNA methylation in BE. Dr. Moinova's DNA methylation test was more than 90 percent accurate in detecting BE or in recognizing an esophagus as normal in a set of more than 300 esophagus endoscopy samples collected by Dr. Chak's multicenter BETRNet team. Under sponsorship from the SPORE and BETRNet programs, Dr. Chak then led a clinical trial in which 86 individuals were tested using the swallowable esophageal balloon device. Dr. Moinova's DNA assay of these balloon samples was again more than 90 percent accurate, with 90.3 percent sensitivity for detecting individuals with BE and 91.7 percent specificity for correctly identifying individuals who were normal.

Infographic explaining advantages of a new diagnostic for Barret's Esophagus compared to traditional endoscopy. Credit: Carla Schaffer / Moinova et al. / AAAS
"Our goal is ," said Dr. Chak. "Symptoms of Barrett's esophagus, such as heartburn, can also be commonly seen in individuals who have acid reflux disease without BE. These symptoms can easily be treated by over the counter medications so people often don't get tested for BE, particularly by an invasive test such as endoscopy. As a result, when individuals develop EAC, 95 percent of the time the presence of the prior Barrett's esophagus was undetected and unknown. We wanted an easier, less costly test that could provide a practical way for screening and early detection of individuals with BE, who can then be followed closely to prevent development of EAC."

In the clinical trial, patients tolerated the balloon test well, with 82 percent reporting little to no anxiety, pain, or choking, 93 percent stating they would repeat the procedure again, and 95 percent stating they would recommend the test to others. The balloon device that patients swallowed is a pill-sized capsule attached to a thin silicone catheter. After delivery to the stomach, the small balloon was inflated by injecting air through the catheter. The inflated balloon was maneuvered to swab the lower esophagus near the stomach, the region where BE begins, and obtain a sample of the lining cells. Surface texturing on the balloon increased the effectiveness of the sampling. The balloon was then deflated through the catheter and inverted back into the capsule, thus protecting the esophagus sample from dilution or contamination. After retrieval of the capsule through the mouth, DNA was extracted from the balloon surface for the DNA methylation test.

In an earlier study, the team had previously identified that VIM DNA methylation is common in BE. The genomic technology employed in the new study discovered CCNA1 DNA methylation is equally common in BE. "Having two accurate biomarkers increases confidence in our ability to correctly diagnose Barrett's esophagus," said Dr. Moinova. "Taken together, our findings show that non-endoscopic sampling paired with molecular tests for the methylated VIM and CCNA1 biomarkers is effective in addressing the need for simple, non-invasive, safe, and accurate Barrett's esophagus screening."

Video of Amitabh Chak performing a minimally invasive new screening method for detecting esophageal cancer risk. Credit: Case Western Reserve University School of Medicine

Dr. Willis is currently leading an NIH supported effort to implement the VIM and CCNA1 DNA tests as a standardized clinical test that will be provided by the University Hospital's pathology department. Dr. Markowitz noted that, "We are fortunate to be the only academic medical center in the country to which the NIH has awarded both a GI Cancers SPORE and a BETRNet program. The $18 million in support from these NIH awards has allowed us to build a premier team for developing new approaches for early detection, prevention and treatment of GI cancers. However, credit for this advance most importantly belongs to each of the patients who so generously participated in the clinical trial of this exciting new technology."

Explore further: Researchers present findings on promising biomarker for esophageal cancer

More information: H.R. Moinova el al., "Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus," Science Translational Medicine (2018). … scitranslmed.aao5848

Related Stories

Researchers present findings on promising biomarker for esophageal cancer

May 5, 2014
A new biomarker for esophageal cancer shows promise in improving screening for this deadly disease and its precursor, Barrett's esophagus.

New minimally invasive test identifies patients for Barrett's esophagus screening

January 29, 2015
A new minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression can be used to identify patients with reflux symptoms who warrant endoscopy to diagnose Barrett's esophagus, according to ...

Esophageal cancer 'cell of origin' identified

October 11, 2017
Columbia University Medical Center (CUMC) researchers have identified cells in the upper digestive tract that can give rise to Barrett's esophagus, a precursor to esophageal cancer. The discovery of this "cell of origin" ...

New studies add to understanding of treatments for Barrett's esophagus

October 6, 2017
The October issue of GIE: Gastrointestinal Endoscopy features several new studies evaluating various treatments for Barrett's esophagus (BE). Two of these studies are highlighted below.

Risk of esophageal cancer in patients with Barrett’s esophagus

October 14, 2011
(Medical Xpress) -- A new study published in the New England Journal of Medicine reveals that the risk of patients with Barrett’s esophagus developing adenocarcinoma of the esophagus are not as high as once originally ...

Researchers discover gene variant associated with esophageal cancer

July 28, 2016
Researchers at University Hospitals Case Medical Center have discovered that a rare genetic mutation is associated with susceptibility to familial Barrett esophagus (FBE) and esophageal cancer, according to a new study published ...

Recommended for you

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

Researcher fighting breast cancer with light therapy

October 17, 2018
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.